Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01817790 · ClinicalTrials.gov registry record · Phase 3
Assessment of Fluticasone Propionate on Ocular Allergy Symptoms
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 626
- Enrollment target
NCT01817790 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 626 participants.
The verdict
NCT01817790, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 626 participants
- Enrollment target
Study Summary
This study is designed to investigate the efficacy of fluticasone propionate (FP) on ocular symptoms associated with allergic rhinitis (AR).
Interventions
- DRUG Placebo
- DRUG Fluticasone propionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 626 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01817790
The ClinicalTrials.gov registry entry for NCT01817790 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 626 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01817790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01817790 about?
NCT01817790 is a clinical study titled "Assessment of Fluticasone Propionate on Ocular Allergy Symptoms". This study is designed to investigate the efficacy of fluticasone propionate (FP) on ocular symptoms associated with allergic rhinitis (AR).
What is the current status of trial NCT01817790?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 626 participants. The study started on 2012-12. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01817790?
The interventions under investigation include: Placebo (DRUG), Fluticasone propionate (DRUG).
Who is sponsoring clinical trial NCT01817790?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.